Scholarlink

Background <p>Surgery is the main modality of comprehensive tumor treatment, and there are fewer studies on surgery in lung cancer patients with liver metastases.</p> Methods <p>In this study, clinical data on lung cancer patients with liver metastases were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Patients treated with cancer-directed surgery (CDS) by Propensity Score Matching (PSM) are matched 1:1 to patients not treated with CDS. The impact of CDS treatment and clinical factors on patient prognosis was explored Kaplan–Meier survival analysis, univariate and multivariate Cox analysis, and Cox risk proportional regression models.</p> Results <p>A total of 6,632 lung cancer patients with liver metastases were included in this study, including 83 patients treated with CDS (1.25%) and 6549 patients not treated with CDS (98.75%). By PSM matching, 83 patients not treated with CDS were obtained. Survival analysis showed that the median survival was 9&#xa0;months (95% CI 7–15&#xa0;months) in the CDS group, compared to 3&#xa0;months (95% CI 2–6&#xa0;months) in the No-CDS group. Cox risk proportional regression models indicated that No-CDS, male and N2-N3 staging were prognostic risk factors, whereas chemotherapy were prognostic protective factors. In addition, univariate and multivariate Cox analyses showed that No-CDS and men were independent prognostic risk factors, whereas chemotherapy were independent prognostic protective factors.</p> Conclusions <p>Our findings suggest that CDS treatment can improve the prognosis of patients with lung cancer with liver metastases, which will provide a reference for further randomized controlled clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reevaluating the role of surgery in lung cancer with liver metastases: a propensity score-matched survival analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月12日

查看全文
  • Yongfei Fan,
  • Qiyong Wu,
  • Ming Lou

摘要

Background

Surgery is the main modality of comprehensive tumor treatment, and there are fewer studies on surgery in lung cancer patients with liver metastases.

Methods

In this study, clinical data on lung cancer patients with liver metastases were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Patients treated with cancer-directed surgery (CDS) by Propensity Score Matching (PSM) are matched 1:1 to patients not treated with CDS. The impact of CDS treatment and clinical factors on patient prognosis was explored Kaplan–Meier survival analysis, univariate and multivariate Cox analysis, and Cox risk proportional regression models.

Results

A total of 6,632 lung cancer patients with liver metastases were included in this study, including 83 patients treated with CDS (1.25%) and 6549 patients not treated with CDS (98.75%). By PSM matching, 83 patients not treated with CDS were obtained. Survival analysis showed that the median survival was 9 months (95% CI 7–15 months) in the CDS group, compared to 3 months (95% CI 2–6 months) in the No-CDS group. Cox risk proportional regression models indicated that No-CDS, male and N2-N3 staging were prognostic risk factors, whereas chemotherapy were prognostic protective factors. In addition, univariate and multivariate Cox analyses showed that No-CDS and men were independent prognostic risk factors, whereas chemotherapy were independent prognostic protective factors.

Conclusions

Our findings suggest that CDS treatment can improve the prognosis of patients with lung cancer with liver metastases, which will provide a reference for further randomized controlled clinical trials.